Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEK2 | P51955 | 2/20 | 1.00 |
| ▸ | CDK1 | P06493 | 1/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 1/20 | 1.00 |
| ▸ | TLK2 | Q86UE8 | 6/20 | 0.76 |
| ▸ | PDPK1 | O15530 | 6/20 | 0.74 |
| ▸ | JAK3 | P52333 | 4/20 | 0.74 |
| ▸ | PAK4 | O96013 | 2/20 | 0.70 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.66 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.65 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.65 |
| ▸ | FLT1 | P17948 | 1/20 | 0.65 |
| ▸ | KDR | P35968 | 1/20 | 0.65 |
| ▸ | RET | P07949 | 2/20 | 0.61 |
| ▸ | FLT3 | P36888 | 1/20 | 0.61 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31061298 | 1.00 | NEK2 (1.00) | NEK2CDK1CCNB1TLK2PDPK1 | |
| SCHEMBL20945 | 0.85 | TLK2 (1.00) | NEK2CDK1CCNB1TLK2PDPK1 | |
| SCHEMBL20944 | 0.85 | TLK2 (1.00) | NEK2CDK1CCNB1TLK2PDPK1 | |
| SCHEMBL5728434 | 0.84 | PDPK1 (1.00) | NEK2CDK1CCNB1TLK2PDPK1 | |
| SCHEMBL13080513 | 0.84 | TLK2 (1.00) | NEK2CDK1CCNB1TLK2PDPK1 | |
| SCHEMBL5728440 | 0.84 | PDPK1 (1.00) | NEK2CDK1CCNB1TLK2PDPK1 | |
| SCHEMBL5361523 | 0.81 | PDPK1 (1.00) | NEK2CDK1CCNB1TLK2PDPK1 | |
| SCHEMBL5728671 | 0.81 | PDPK1 (1.00) | NEK2CDK1CCNB1TLK2PDPK1 | |
| SCHEMBL5366002 | 0.81 | PDPK1 (0.80) | NEK2CDK1CCNB1TLK2PDPK1 | |
| SCHEMBL5374151 | 0.81 | PDPK1 (0.78) | NEK2CDK1CCNB1TLK2PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748601-B2 | Selective serine/threonine kinase inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748601-B2 | Selective serine/threonine kinase inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-06-10 | — | — | US | disclosed |
| US-8034821-B2 | Selective serine/threonine kinase inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-10-11 | — | — | US | disclosed |
| US-8034821-B2 | Selective serine/threonine kinase inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-10-11 | — | — | US | disclosed |
| US-20100256171-A1 | SELECTIVE SERINE/THREONINE KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100256171-A1 | SELECTIVE SERINE/THREONINE KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-10-07 | — | — | US | disclosed |
| US-7687506-B2 | Selective serine/threonine kinase inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687506-B2 | Selective serine/threonine kinase inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-03-30 | — | — | US | disclosed |
| US-20090221614-A1 | SELECTIVE SERINE/THREONINE KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (CA) | 2009-09-03 | — | — | US | disclosed |
| US-20090221614-A1 | SELECTIVE SERINE/THREONINE KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (CA) | 2009-09-03 | — | — | US | disclosed |
| US-20070082884-A1 | Selective serine/threonine kinase inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-04-12 | — | — | US | disclosed |
| US-20070082884-A1 | Selective serine/threonine kinase inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082884-A1 | Selective serine/threonine kinase inhibitors | DSTYK, TTK, SBK1 | NEK2 136/4885CDK1 158/4885CCNB1 1406/4885 |
| US-20090221614-A1 | SELECTIVE SERINE/THREONINE KINASE INHIBITORS | DSTYK, TTK, SBK1 | NEK2 136/4885CDK1 158/4885CCNB1 1406/4885 |
| US-20100256171-A1 | SELECTIVE SERINE/THREONINE KINASE INHIBITORS | DSTYK, TTK, SBK1 | NEK2 136/4885CDK1 158/4885CCNB1 1406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.